Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 54, Issue 4, 2016, Pages 461-468

  Jiang, Baohua ^a   Deng, Yupu ^a   Suen, Colin ^a,b   Taha, Mohamad ^a,b   Chaudhary, Ketul R ^a   Courtman, David W ^a   Stewart, Duncan J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Pulmonary arterial hypertension; Right ventricular remodeling; Rodent strains; SU5416; Vascular remodeling

Indexed keywords

CASPASE 3; SEMAXANIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FISCHER 344 RAT; HEART RIGHT VENTRICLE HYPERTROPHY; LEWIS RAT; LUNG HEMODYNAMICS; MORTALITY; NONHUMAN; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANOXIA; DISEASE MODEL; HYPERTENSION, PULMONARY; PATHOLOGY; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT;

ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; INDOLES; PYRROLES; RATS; RATS, INBRED F344; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 84963736344     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0488OC     Document Type: Article

References (25)

1. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001;104:790-795.
2. Zhao YD, Courtman DW, Ng DS, Robb MJ, Deng YP, Trogadis J, Han RN, Stewart DJ. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 2006;35:182-189.
3. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007;28:23-42, vii.
4. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8: 443-455.
5. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121: 2747-2754.
6. Ryan JJ, Marsboom G, Archer SL. Rodent models of group 1 pulmonary hypertension. Handbook Exp Pharmacol 2013;218:105-149.
7. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009;30:376-385.
8. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43:25S-32S.
9. Meyrick B. The pathology of pulmonary artery hypertension. Clin Chest Med 2001;22:393-404, vii.
10. Wagenvoort CA. Plexogenic arteriopathy. Thorax 1994;49:S39-S45.
11. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989;80:1198-1206.
12. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell deathdependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438.
13. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-929.
14. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-L676.
15. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007;175:1280-1289.
16. Alzoubi A, Almalouf P, Toba M, O'Neill K, Qian X, Francis M, Taylor MS, Alexeyev M, McMurtry IF, Oka M, et al. TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. Am J Pathol 2013;183:1779-1788.
17. de Raaf MA, Schalij I, Gomez-Arroyo J, Rol N, Happé C, de Man FS, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, Bogaard HJ. SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction. Eur Respir J 2014;44:160-168.
18. Takemiya K, Kai H, Yasukawa H, Tahara N, Kato S, Imaizumi T. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 2010;105: 409-417.
19. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-450.
20. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19: 1178-1180.
21. Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, Caruso P, Southwood M, Foster WS, Morrell NW, et al. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation 2014;129: 2125-2135.
22. Assadnia S, Rapp JP, Nestor AL, Pringle T, Cerilli GJ, Gunning WT III, Webb TH, Kligman M, Allison DC. Strain differences in neointimal hyperplasia in the rat. Circ Res 1999;84:1252-1257.
23. Nikolova S, Lee T-Y, Bartha R.The severity of ischemia varies in Sprague-Dawley rats from different vendors. ISRN Stroke 2014; 2014:9196521-9196529.
24. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010;122: 164-172.
25. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, et al.; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114: 1883-1891.